Top

Published in:

01-09-2009 | Original Article

Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation

Authors: G. Hutter, M. Scheubner, G. Ott, Y. Zimmermann, K. Hübler, S. Roth, S. Stilgenbauer, J. Kalla, H. Stöcklein, W. Hiddemann, M. Dreyling

Published in: Annals of Hematology | Issue 9/2009

Abstract

Mantle cell lymphoma (MCL) is a distinct subentity of non-Hodgkin lymphoma, characterized by the chromosomal translocation t(11;14)(q13;q32) leading to an overexpression of cyclin D1 in virtually all cases. However, additional cytogenetic aberrations are apparent in the vast majority of MCL. Applying LOH analysis in 52 MCL patient samples, we confirmed frequent alterations in 9p21 (28.6%) and p53 (28.9%) but also detected allelic losses in 1p21, 9q21, 13q13-14, 13q31-32, 17p13.1, and 17p13.3 in 28–45% of cases and allelic gains in 3q27-28 and 19p13.3 in 14–22% of cases. In addition, losses in the 2p23 and 7q22-35 genomic regions not previously described to be altered in MCL were identified in up to 20% of cases. Applying multivariate analysis, a cluster of genomic aberrations including 1p21, 3q27, 7q22-36, 6p24, 9p21, 9q31, and 16p12 alterations was identified which was closely associated to cell proliferation as determined by Ki67 immunostaining. This proliferation-dependent network of oncogenic alterations complements the previously identified proliferation expression signature described by RNA expression profiling in MCL.

Available only for authorised users

Allen JE, Hough RE, Goepel JR, Bottomley S, Wilson GA, Alcock HE et al (2002) Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol 116(2):291–298 doi:10.1046/j.1365-2141.2002.03260.x PubMedCrossRef

Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K et al (1992) Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16(7):637–640 doi:10.1097/00000478-199207000-00001 PubMedCrossRef

Bastard C, Raux G, Fruchart C, Parmentier F, Vaur D, Penther D, Troussard X, Nagib D, Lepretre S, Tosi M, Frebourg T, Tilly H (2007) Comparison of a quantitative PCR method with FISH for the assessment of the four aneuploidies commonly evaluated in CLL patients. Leukemia 21(7):1460–1463 doi:10.1038/sj.leu.2404727 PubMedCrossRef

Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L et al (1999) Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93(12):4365–4374PubMed

Bentz M, Plesch A, Bullinger L, Stilgenbauer S, Ott G, Müller-Hermelink HK, Baudis M et al (2000) t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27(3):285–294 doi:10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M PubMedCrossRef

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529 doi:10.1073/pnas.242606799 PubMedCrossRef

Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123(3):437–448 doi:10.1016/j.cell.2005.08.011 PubMedCrossRef

Chopin V, Leprince D (2006) Chromosome arm 17p13.3: could HIC1 be the one? Med Sci (Paris) 22(1):54–61

Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102(39):13944–13949 doi:10.1073/pnas.0506654102 PubMedCrossRef

10.

Cvekl A Jr, Zavadil J, Birshtein BK, Grotzer MA, Cvekl A (2004) Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene. Eur J Cancer 40(16):2525–2532 doi:10.1016/j.ejca.2004.08.005 PubMedCrossRef

11.

de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ et al (2004) Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 13(17):1827–1837 doi:10.1093/hmg/ddh195 PubMedCrossRef

12.

Doehner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Doehner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910–1916 doi:10.1056/NEJM200012283432602 CrossRef

13.

Dreyling M, Bergsagel PL, Gordon LI, Cotter FE (2006) Mantle cell lymphoma and other t(11;14) disorders: How biology can drive therapy. ASCO Educational book, 476–484

14.

Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Muller-Hermelink HK, Bentz M et al (1997) Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57(20):4608–4614PubMed

15.

Dreyling MH, Roulston D, Bohlander SK, Vardiman J, Olopade OI (1998) Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer 22(1):72–78 doi:10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.0.CO;2-K PubMedCrossRef

16.

Ek S, Bjorck E, Porwit-MacDonald A, Nordenskjold M, Borrebaeck CA (2004) Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica 89(6):686–695PubMed

17.

Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M (1998) Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91(12):4677–4685PubMed

18.

Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A (2005) Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23(26):6364–6369 doi:10.1200/JCO.2005.05.019 PubMedCrossRef

19.

Flordal TE, Ichimura K, Collins VP, Walsh SH, Barbany G, Hagberg A et al (2007) Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 31(9):1219–1230 doi:10.1016/j.leukres.2006.10.022 CrossRef

20.

Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC et al (2006) Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 103(7):2352–2357 doi:10.1073/pnas.0510441103 PubMedCrossRef

21.

Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al (1996) p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87(8):3351–3359PubMed

22.

Hernandez L, Bea S, Pinyol M, Ott G, Katzenberger T, Rosenwald A et al (2005) CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 65(6):2199–2206 doi:10.1158/0008-5472.CAN-04-1526 PubMedCrossRef

23.

Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA (1994) Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91(2):709–713 doi:10.1073/pnas.91.2.709 PubMedCrossRef

24.

Hovig E, Smith-Sorensen B, Uitterlinden AG, Borresen AL (1992) Detection of DNA variation in cancer. Pharmacogenetics 2(6):317–328 doi:10.1097/00008571-199212000-00011 PubMedCrossRef

25.

Hutter G, Scheubner M, Zimmermann Y, Kalla J, Katzenberger T, Hubler K et al (2006) Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. Genes Chromosomes Cancer 45(2):203–210 doi:10.1002/gcc.20277 PubMedCrossRef

26.

Jaffe ES, Harris NL, Stein H et al (2001) World Health Organization classification of tumors: pathology and genetics of tumors of haemotopoetic and lymphoid tissues. IARC, Lyon, France

27.

Katzenberger T, Petzoldt C, Höller S, Mäder U, Kalla J, Adam P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G (2006) The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 107(8):3407 doi:10.1182/blood-2005-10-4079 PubMedCrossRef

28.

Kohlhammer H, Schwaenen C, Wessendorf S, Holzmann K, Kestler HA, Kienle D et al (2004) Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104(3):795–801 doi:10.1182/blood-2003-12-4175 PubMedCrossRef

29.

Konishi H, Sugiyama M, Mizuno K, Saito H, Yatabe Y, Takahashi T et al (2003) Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer. Oncogene 22(12):1892–1905 doi:10.1038/sj.onc.1206304 PubMedCrossRef

30.

Lovec H, Grzeschiczek A, Kowalski MB, Moroy T (1994) Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13(15):3487–3495PubMed

31.

Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H et al (1998) Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21(4):298–307 doi:10.1002/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3.0.CO;2-U PubMedCrossRef

32.

Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T et al (2003) Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120(3):434–441 doi:10.1046/j.1365-2141.2003.04121.x PubMedCrossRef

33.

O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043):839–843 doi:10.1038/nature03677 PubMedCrossRef

34.

Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S et al (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64(9):3087–3095 doi:10.1158/0008-5472.CAN-03-3773 PubMedCrossRef

35.

Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG, Muller-Hermelink HK (1997) Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89(4):1421–1429PubMed

36.

Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL et al (1997) Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89(1):272–280PubMed

37.

Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL et al (1998) p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood 91(8):2977–2984PubMed

38.

Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V et al (2006) Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Haematol 132(3):303–316 doi:10.1111/j.1365-2141.2005.05883.x CrossRef

39.

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185–197 doi:10.1016/S1535-6108(03)00028-X PubMedCrossRef

40.

Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I et al (2005) Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105(11):4445–4454 doi:10.1182/blood-2004-10-3907 PubMedCrossRef

41.

Salaverria I, Zettl A, Beà S, Moreno V, Valls J, Hartmann E et al (2007) Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25(10):1216–1222 doi:10.1200/JCO.2006.08.4251 PubMedCrossRef

42.

Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P (2000) Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 97(6):2773–2778 doi:10.1073/pnas.050400997 PubMedCrossRef

43.

Scheubner M, Huebler K, Hutter G, Ott G, Hiddemann W, Dreyling MH (2002) Oncogenic Hirarchy of Genomic Alterations in MCL: p16Ink4a Deletions and 13q14 alterations suggest a common mechanism of cell cycle alteration. 44th Annual Meeting of the American Society of Hematology, Philadelphia. Blood 100:565a

44.

Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G, Kneba M et al (2005) Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer 93(8):939–945 doi:10.1038/sj.bjc.6602795 PubMedCrossRef

45.

Stilgenbauer S, Schaffner C, Winkler D, Ott G, Leupolt E, Bentz M et al (2000) The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 11(Suppl 1):127–130 doi:10.1023/A:1008315003377 PubMedCrossRef

46.

Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, Dohner K et al (1998) Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene 16(14):1891–1897 doi:10.1038/sj.onc.1201764 PubMedCrossRef

47.

Tamaru JI, Kawana H, Takahashi Y, Takahashi N, Isobe K, Hirai A et al (1999) Expression of cell cycle regulating proteins in an unusual transformation of mantle cell lymphoma. Leuk Lymphoma 36(1–2):128–137PubMed

48.

Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A et al (2005) European MCL Network. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 131(1):29–38 doi:10.1111/j.1365-2141.2005.05716.x PubMedCrossRef

49.

Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226(4678):1097–1099 doi:10.1126/science.6093263 PubMedCrossRef

50.

Volkmann M, Schiff JH, Hajjar Y, Otto G, Stilgenbauer F, Fiehn W et al (2001) Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med 79(10):594–600 doi:10.1007/s001090100244 PubMedCrossRef

Title: Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation
Authors: G. Hutter
M. Scheubner
G. Ott
Y. Zimmermann
K. Hübler
S. Roth
S. Stilgenbauer
J. Kalla
H. Stöcklein
W. Hiddemann
M. Dreyling
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 9/2009
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0686-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2009

Rare hemoglobin variant Hb I Philadelphia in North Indian family

Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies

Synchronous null-cell anaplastic large cell lymphoma and multiple myeloma

Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia

The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin’s lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience

Systemic amyloidosis complicated with peliosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page